CCIA
ANIK icon

Campbell & Co Investment Adviser’s Anika Therapeutics ANIK Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-6,427
Closed -$265K – 150
2015
Q1 		$265K Sell
6,427
-20,315
-76% -$821K 0.17% 164
2014
Q4 		$1.09M Sell
26,742
-21,625
-45% -$845K 0.67% 50
2014
Q3 		$1.77M Buy
+48,367
New +$2.09M 0.91% 38

Other funds holding ANIK

TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LCP
Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Campbell & Co Investment Adviser's ANIK Position: Q2 2015 in Review

Campbell & Co Investment Adviser sold out of Anika Therapeutics (ANIK) in Q2 2015, closing a stake of 6,427 shares — an estimated $265K sold.

Campbell & Co Investment Adviser first reported a position in ANIK in Q3 2014 and held it in 3 quarters. The position peaked at $1.77M in Q3 2014. 136 funds tracked by Wall St. Rank hold ANIK as of Q2 2015.

  • Campbell & Co Investment Adviser reported no remaining Anika Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 6,427 Anika Therapeutics shares in Q2 2015, an estimated $265K.
  • Campbell & Co Investment Adviser first reported a position in Anika Therapeutics in Q3 2014 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Anika Therapeutics position peaked at $1.77M in Q3 2014.
  • 136 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2015.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2015, filed 7 Aug 2015.